Prostate cancer is one of the most common cancers among men. Many cases grow slowly and may never become life-threatening. Because of this, doctors often recommend a management approach called “active ...

A novel immunotherapy combination is proving to be both safe and manageable for patients with prostate cancer, according to updated Phase 1 trial data presented at the 2026 ASCO Genitourinary Cancers ...

Baseline T may provide valuable information about prognosis.

In people with type 2 diabetes in the world's richest countries, deaths from cardiovascular disease are declining while ...

A recent study reveals a troubling increase in dementia-related deaths among individuals with type 2 diabetes in wealthy nations, despite declines in other mortality rates, highlighting the urgent ...

In this retrospective study, researchers sought to determine the efficacy, safety, and effectiveness of a reduced ARSI dose compared to a full dose in non-metastatic castration-resistant prostate ...

Partners and family members could be the first to notice ...

The findings, published in JAMA Network Open, were reported by Cristian Udovicich of the Odette Cancer Centre at Sunnybrook Health Sciences Centre, Toronto, Canada, and colleagues. The investigators ...

Development director hired to help secure funds, long-term stability ...

Cancers emerge from many different paths. One path begins early, in embryonic development, when a protein complex called PRC2, which regulates cell differentiation, identity, and plasticity, becomes ...

The beloved Buc-ees gas station chain may not be so beloved after all.

Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced publication of efficacy and safety results from the PIK3CA ...